About DRG Epidemiology
DRG’s Epidemiology provides bottom-up, patient-level forecasts, detailing disease trends from 10- to 20-year outlook periods to help you validate investments and identify growth opportunities in your markets of interest.
All of our epidemiological data, methods and insight are distributed via DRG’s Insights Platform, allowing the user to easily navigate between world regions and patient populations, as well as download epidemiological forecast data into an MS Excel format for offline use.
All epidemiological forecasts may be supplemented with custom deliverables, such as:
- Chart reviews or more granular stratification using DRG’s in-house real world datasets or physician survey data
- Customized and interactive patient flow models or additional subpopulations or metrics
- Expanded geographical coverage or extended forecast periods beyond those available
Our robust patient population sizing data includes therapeutic coverage of 140+ indications and 3400+ patient subpopulations, including extensive oncology subpopulation data by stage, line of therapy, and biomarker, as well as continually expanding niche and rare disease coverage.
The geographic breadth of data includes mature market (G7) reporting for all 140+ indications, as well as 90% global population coverage for the high-profile diseases, and expanded penetration for emerging and rest-of-world markets in select indications.
For over 20 years, our data and methodology have been developed and refined by DRG’s Epidemiology team of industry-leading subject matter experts, driven by rigorous methodology to uncover the impact of exposure, risk, and treatment, in addition to historical trends and age and gender cohorts.
All of our epidemiological forecasts are accompanied by a transparent description of our methods and data sources, the details of our systematic review underlying each forecast and associated summary evidence tables, and access to the authoring epidemiologist.
- Mature Markets Data
- Key Findings
- Event Rate of Sepsis per 1,000 Among People of All Ages in 2016 and 2026
- Relative Sizes of Contributing Factors to the Trend in Events of Sepsis over the Next Ten Years
- Analysis of Diagnosed Events of Severe Sepsis by Pathogen
- Epidemiology Data
- Diagnosed Events
- Primary Site of Infection of Severe Sepsis
- Drug Treatment
- Reference Materials
- Literature Review
- Risk/Protective Factors
Author(s): Amy Bradshaw Kaiser, MS; Lade Ayodele
Amy Kaiser joined Decision Resources Group as an associate epidemiologist in 2017. Her focus is on the epidemiology of infectious diseases and niche and rare diseases. She holds an MS in Epidemiology from the University of Massachusetts, Amherst and a BA in International Relations from Mount Holyoke College. Prior to joining Decision Resources Group, she worked as a human health research associate at a environmental consulting firm where her epidemiology research focused on occupational and environmental exposures and associated outcomes.
Dr. Ayodele has expertise in forecasting disease populations and is an epidemiology expert in chronic diseases including cancers and cardiovascular diseases, in both the major and emerging pharmaceutical markets. Prior to joining Decision Resources Group, she researched antiretroviral therapy funding, availability and access at the Clinton Foundation Center for Strategic HIV Operations Research. More recently, she was a Medical Innovation and Leadership fellow at Blue Cross Blue Shield of Massachusetts, where she researched and developed strategic plans on health care utilization and quality improvement. Dr. Ayodele holds a Master in Public Health degree (quantitative methods concentration) from Harvard and a medical degree from the University of Ibadan in Nigeria. She is currently pursuing a in epidemiology at Boston University School of Public Health with a focus in pharmacoepidemiology.